Word: inhibitors
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...meantime, I've gone on a so-called proton-pump inhibitor, a new kind of prescription drug that cuts down on acid production. I've also been given a list of changes to make in my life-style. Let's see: I don't drink or smoke or eat fatty foods, so I can't really stop. I'm not obese or even a little overweight, so losing weight won't help. That leaves giving up my beloved caffeine and my even more beloved bedtime snack. We'll see. I'm not making any promises...
...diet" that was high in fat and cholesterol, then measured the plaque buildup on the walls of each aorta, the large artery that carries blood from the heart to the rest of the body. Meanwhile, they injected one group of mice with endostatin, another with a different blood-vessel inhibitor called TNP-470 and a control group with an inert saline solution. Twenty weeks later the researchers again measured plaque in the mouse aortas. The results were startling: the endostatin group averaged 85% less plaque buildup and the TNP-470 group 70% less than those in the control group...
Tell that to Dr. Philip Needham, father of the cox-2 inhibitor, who calls the white paper Palmer presented to the FDA panel "a predictable effort to protect their drug." If you want evidence that Celebrex works, he says, just ask the 13,000 arthritis patients who took part in its trial. "We're getting letters saying, 'Please don't take us off,'" Needham says. And the side effects? Pretty close to placebo levels...
...Steven Abramson, chairman of the FDA advisory panel, was impressed--and not at all surprised that the big drug companies were kicking up a fuss. "The cox-2 inhibitor will make it very difficult for them to compete," he says. Which could explain why Merck, Johnson & Johnson and Glaxo Wellcome are rushing to get their own versions into trial as fast as possible...
...initial trial consisted of 29 individuals with types I and II diabetes, who were administered the oral drug for a month. Future trials will be conducted on a larger scale and will continue to study the effects of the inhibitor on blindness. If the next study, which consists of a thousand patients, proves effective, King and Aiello say they will send their findings to the FDA for approval...